Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of β-D-Mannuronic Acid (M2000)

• Published in: Current drug discovery technologies Vol. 18; no. 5; p. e17092020186049
• Main Authors: Nikouei Moghaddam, Mohamad Reza, Movahedi, Monireh, Bananej, Maryam, Najafi, Soheil, Moghadam, Nahid Beladi, Saadat, Payam, Mokhtarian, Fariba, Mirshafiey, Abbas
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 2021
• Subjects: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Hexuronic Acids; Humans; Multiple Sclerosis - drug therapy; toxicology; Mannuronic acid; NSAIDs; multiple sclerosis; drug safety; biochemical markers; M2000
• ISSN: 1875-6220
• DOI: 10.2174/1570163817999200918104333

Multiple sclerosis is an autoimmune chronic inflammatory disease of the central nervous system that can lead to some serious disabilities. Despite using various immunomodulatory and anti-inflammatory drugs that have therapeutic effects, they cannot reduce its progression completely and have some unwanted side effects too. The immunomodulatory and anti-inflammatory effects of the β-D-Mannuronic acid (M2000) have been proven in several surveys, and the present research was designed to determine its toxicity and therapeutic effects in MS patients.
This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of the β-D-Mannuronic acid for six months, and 15 healthy people as a control group. Serum levels of Urea, Creatinine, GGT, Vitamin D3, Uric acid, and Anti-Phospholipids were compared to evaluate the therapeutic and possible toxic effects of this drug after this period.
Non- toxic effects through the study of urea, creatinine, GGT, and non-significant changes in uric acid and anti-Phospholipids levels, besides a significant rise in vitamin, D3 levels in the M2000 treated cases were found.
Our results suggested that β-D-Mannuronic acid is a safe drug and has no toxicity when administered orally and also has some therapeutic effects in MS patients.